A vaccine that uses the same method as Pfizer’s products to prevent people from becoming seriously ill due to Covid-19 is one step closer to being approved for use in Australia.
The Therapeutic Goods Administration said on Thursday that the American medical company Moderna has obtained an interim decision on its coronavirus vaccine Elasomeran.
Provisional determination means that Moderna can apply for provisional registration of vaccines in the drug register maintained by the Australian authorities.
In other words, the vaccine removes important barriers to approval.
“It is expected that Moderna will submit an application for provisional registration soon,” TGA said in a statement.
“Importantly, registration and supply in Australia will only begin if the TGA approved vaccine is safe and effective.”
Australia has ordered 25 million doses of Moderna vaccine, 10 million doses will be supplied this year, and the rest will be supplied next year.
It is expected that the dose prepared by 2022 will be a booster injection to be able to deal with emerging virus variants.
Both Moderna and Pfizer use a cutting-edge science called mRNA in their coronavirus vaccines.
The “m” in the acronym stands for messenger, and RNA is the ribonucleic acid found in human cells.
Vaccines use “messenger” information to teach cells how to make spike proteins, which are then recognized as foreign by the body, prompting them to establish an immune response.
If the vaccine recipient is infected with the coronavirus, then this response will come in handy because the body already knows how to prevent it.
TGA stated that the Moderna vaccine will be considered for individuals over 12 years of age.
It is currently used in several other countries/regions.